Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Autologous TIL 13831 TCR transduced T cells |
Synonyms | |
Therapy Description |
Autologous TIL 13831 TCR transduced T cells are T-cells isolated from a patient and engineered to express a T-cell receptor (TCR) that targets an MHC class I-restricted tyrosinase peptide, potentially resulting in increased immune response against tyrosinase-expressing tumors (PMID: 20624956). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Autologous TIL 13831 TCR transduced T cells | Autologous TIL 13831 TCR transduced T cells are T-cells isolated from a patient and engineered to express a T-cell receptor (TCR) that targets an MHC class I-restricted tyrosinase peptide, potentially resulting in increased immune response against tyrosinase-expressing tumors (PMID: 20624956). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02870244 | Phase I | Autologous TIL 13831 TCR transduced T cells | Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes | Recruiting | USA | 0 |